Literature DB >> 9647867

International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

A J Harmar1, A Arimura, I Gozes, L Journot, M Laburthe, J R Pisegna, S R Rawlings, P Robberecht, S I Said, S P Sreedharan, S A Wank, J A Waschek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9647867      PMCID： PMC6721840     

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN： 0031-6997            Impact factor:   25.468


× No keyword cloud information.
  81 in total

1.  Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: blockade by protein synthesis inhibition.

Authors:  O Sorg; P J Magistretti
Journal:  J Neurosci       Date:  1992-12       Impact factor: 6.167

2.  Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions.

Authors:  B D Shivers; T J Görcs; P E Gottschall; A Arimura
Journal:  Endocrinology       Date:  1991-06       Impact factor: 4.736

3.  A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes.

Authors:  Y Gozes; D E Brenneman; M Fridkin; R Asofsky; I Gozes
Journal:  Brain Res       Date:  1991-02-01       Impact factor: 3.252

4.  The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranes.

Authors:  P Robberecht; M C Woussen-Colle; P De Neef; P Gourlet; L Buscail; A Vandermeers; M C Vandermeers-Piret; J Christophe
Journal:  FEBS Lett       Date:  1991-07-29       Impact factor: 4.124

5.  Vasoactive intestinal polypeptide: biologic role in health and disease.

Authors:  S I Said
Journal:  Trends Endocrinol Metab       Date:  1991 May-Jun       Impact factor: 12.015

6.  Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines.

Authors:  J Luis; S I Said
Journal:  Peptides       Date:  1990 Nov-Dec       Impact factor: 3.750

7.  Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist.

Authors:  I Gozes; E Meltzer; S Rubinrout; D E Brenneman; M Fridkin
Journal:  Endocrinology       Date:  1989-12       Impact factor: 4.736

8.  Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat.

Authors:  J M Hill; I Gozes; J L Hill; M Fridkin; D E Brenneman
Journal:  Peptides       Date:  1991 Jan-Feb       Impact factor: 3.750

9.  Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38).

Authors:  A Miyata; L Jiang; R D Dahl; C Kitada; K Kubo; M Fujino; N Minamino; A Arimura
Journal:  Biochem Biophys Res Commun       Date:  1990-07-31       Impact factor: 3.575

10.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

Authors:  T Ishihara; R Shigemoto; K Mori; K Takahashi; S Nagata
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173
View more
  146 in total

1.  Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor.

Authors:  J Hannibal; F Jamen; H S Nielsen; L Journot; P Brabet; J Fahrenkrug
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

2.  Pituitary adenylyl cyclase-activating polypeptide stimulates DNA synthesis but delays maturation of oligodendrocyte progenitors.

Authors:  M Lee; V Lelievre; P Zhao; M Torres; W Rodriguez; J Y Byun; S Doshi; Y Ioffe; G Gupta; A E de los Monteros; J de Vellis; J Waschek
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

3.  Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors.

Authors:  E M Lutz; C J MacKenzie; M Johnson; K West; J A Morrow; A J Harmar; R Mitchell
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  IL-6 and PACAP receptor expression and localization after global brain ischemia in mice.

Authors:  Tomoya Nakamachi; Masashi Tsuchida; Nobuyuki Kagami; Sachiko Yofu; Yoshihiro Wada; Motohide Hori; Daisuke Tsuchikawa; Akira Yoshikawa; Nori Imai; Keisuke Nakamura; Satoru Arata; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2012-06-06       Impact factor: 3.444

5.  Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression.

Authors:  Margarita Ivanova; Stiliana Belcheva; Iren Belcheva; Negrin Negrev; Roman Tashev
Journal:  Psychopharmacology (Berl)       Date:  2011-12-08       Impact factor: 4.530

6.  Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice.

Authors:  S Shen; C Spratt; W J Sheward; I Kallo; K West; C F Morrison; C W Coen; H M Marston; A J Harmar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

7.  Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.

Authors:  Venkat Subramaniam; Gin Chuang; Huijing Xia; Brendan Burn; Jessica Bradley; Jerome L Maderdrut; David H Coy; Kurt J Varner
Journal:  Peptides       Date:  2017-07-15       Impact factor: 3.750

Review 8.  Regulation of basal tone, relaxation and contraction of the lower oesophageal sphincter. Relevance to drug discovery for oesophageal disorders.

Authors:  R Farré; D Sifrim
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

9.  Vasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission.

Authors:  Kai Yang; Catherine H Trepanier; Hongbin Li; Michael A Beazely; Ethan A Lerner; Michael F Jackson; John F MacDonald
Journal:  Hippocampus       Date:  2009-09       Impact factor: 3.899

Review 10.  PACAP signaling to DREAM: a cAMP-dependent pathway that regulates cortical astrogliogenesis.

Authors:  Mario Vallejo
Journal:  Mol Neurobiol       Date:  2009-02-24       Impact factor: 5.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.